Mevidalen

Mevidalen

Clinical data
Other names	LY-3154207; LY3154207
Identifiers
IUPAC name 2-(2,6-dichlorophenyl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone
CAS Number	1638667-79-4
PubChem CID	86290953
IUPHAR/BPS	10506
ChemSpider	58985571
UNII	4A3702A96F
KEGG	D11826
ChEMBL	ChEMBL3421729
Chemical and physical data
Formula	C24H29Cl2NO3
Molar mass	450.40 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@H]1C2=CC=CC(=C2C[C@@H](N1C(=O)CC3=C(C=CC=C3Cl)Cl)CO)CCC(C)(C)O
InChI InChI=1S/C24H29Cl2NO3/c1-15-18-7-4-6-16(10-11-24(2,3)30)19(18)12-17(14-28)27(15)23(29)13-20-21(25)8-5-9-22(20)26/h4-9,15,17,28,30H,10-14H2,1-3H3/t15-,17+/m0/s1 Key:XHCSBQBBGNQINS-DOTOQJQBSA-N

Mevidalen (developmental code name LY-3154207) is a dopaminergic drug which is under development for the treatment of Lewy body disease, including those with Parkinson's disease. It acts as a selective positive allosteric modulator (PAM) of the dopamine D₁ receptor. The drug is orally active and crosses the blood–brain barrier. It is a tetrahydroisoquinoline and is a close analogue of DETQ, another D₁ receptor PAM. Mevidalen has been found to have wakefulness-promoting effects in sleep-deprived humans.Side effects of mevidalen have been reported to include increased heart rate and blood pressure, insomnia, dizziness, nausea, vomiting, anxiety, nervousness, fatigue, headaches, palpitations, and contact dermatitis, as well as falls in those with dementia. As of March 2022, mevidalen is in phase 2 clinical trials for the treatment of Lewy body disease. Besides for movement disorders and dementia, D₁ receptor PAMs like mevidalen might have value in the treatment of certain neuropsychiatric disorders, such as depression, excessive somnolence, and attention deficit hyperactivity disorder.

External links

• Mevidalen - AdisInsight